Editor-in-Chief, Deputy Editor 2017-2019

 

Editor-in-Chief:

Tom MOREELS

 

Deputy Editor:

Nicolas LANTHIER

 

Mini-Review



Oral fluoropyrimidines in colorectal cancer : A door open to the future ?


Price: €10,00

Since its first use 40 years ago, 5-fluorouracil (5-FU) has become an unquestionable component of colorectal cancer treatment. It is also now well established that infusional 5-FU administration, in combination with leucovorin, is associated with better tolerance and at least equal efficacy than bolus administration. However, requiring catheter and infusion pumps, infusional 5-FU adminis-tration is costly, rather inconvenient for patients and potentially associated with morbidity, initiating subsequent oral chemothera-py development. To address intravenous 5-FU related issues, oral fluoropyrimidines have been developed such as capecitabine, pref-erentially converted to 5-FU into tumour cells, and UFT, able of bypassing intestinal dihydropyrimidine deshydrogenase. We dis-cuss in this article current oral fluoropyrimidines achievements in colorectal cancer management. [Product Details...]